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CORRELATION BETWEEN UROFLOWMETRY, PROSTATE 
VOLUME, POSTVOID RESIDUE, AND LOWER URINARY 
TRACT SYMPTOMS AS MEASURED BY THE 
INTERNATIONAL PROSTATE SYMPTOM SCORE
K. EZZ EL DIN, L. A, L. M. KIEMENEY, M. J. A. M, d e  WILDT, F. M. J. DEBRUYNE,
AND J. J. M. C. H. DE l a  ROSETTE
ABSTRACT
Objectives. To evaluate the relation between lower urinary tract symptoms (LUTS) as measured by the
International Prostate Symptom Score (IPSS) and noninvasive objective parameters of lower urinary tract 
dysfunction.
Methods. Eight hundred three consecutive patients with LUTS and/or benign prostatic hyperplasia were 
evaluated with IPSS, uroflowmetry, prostate volume estimation, and postvoiding residue measurement. The 
relations between these parameters were quantified by means of Spearman correlation coefficients. 
Results. Statistically significant but weak correlations were found between the IPSS and results of uroflow- 
metry and postvoiding residual urine. There was no correlation between the IPSS and results of prostate 
volume measurements.
Conclusions. The correlation between objective noninvasive parameters of lower urinary tract dysfunction 
and LUTS is weak. UROLOGY 48: 393-397, 1996.
The development of prostatic enlargement sec­ondary to benign prostatic hyperplasia (BPH) and the development of lower urinary tract symp­
toms (LUTS) are frequent events in aging males.1 
Most patients who seek medical advice do so be­
cause of bothersome symptoms,2 Consequently, 
symptoms have become the major focus in the 
management of bladder outlet obstruction due to 
BPH.3 Many urologists use the symptoms as the 
basis for diagnosis of outlet obstruction and for 
assessment of treatment efficacy. A number of 
symptom scores have been designed in search of 
an objective and structured history of symptoms. 
Nowadays, the most widely used symptom score 
is the international Prostate Symptom Score 
(IPSS). It is generally assumed that the IPSS is a 
reliable and valid instrument to measure subjec­
tive severity of symptoms and symptom progrès-
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sion over time.4 Besides subjective parameters, 
changes in objective parameters are used to eval­
uate treatment success. Because treatment of BPH 
usually focuses on bladder outlet obstruction, the 
objective parameters ideally quantify the improve­
ment in grade of obstruction. Urodynamic inves­
tigation with pressure-flow analysis is the refer­
ence standard to measure grade of obstruction. Its 
role in the diagnostic armamentarium of BPH, 
however, is controversial. Urodynamic investiga­
tions are invasive and time consuming.5 Moreover, 
there is a large equivocal area in the pressure-flow 
relationship in which “ruling-out” obstruction is 
difficult.
To document obstruction, most urologists still 
use noninvasive objective parameters such as uri­
nary flow rate, residual urine, and prostate vol­
ume. Uroflowmetry is almost universally available 
and easy to perform, and it is probably the most 
frequently used test in urology today.0,7 Uroflow 
and, especially, maximum flow rate (Qmax) are 
used equivalently with pressure-flow studies to de­
fine bladder outlet obstruction. Although uroflow 
describes the relation between detrusor activity 
and outflow, current opinion holds that if Qmax 
is lower than 10 mL/s, the patient is most likely
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TABLE I. Results of age, uroflow, prostate volume, and postvoiding residual urine 
measurements according to three classes of the International Prostate Symptom Score 
(mild, moderate, and severe)
Total IPSS
All Patients 
(n - 729)
Mild
(<8; n = 71 )
Moderate 
(8-19; n = 392)
Severe 
(>19; n = 266)
Mean SD Mean SD Mean SD Mean SD Significance
Age (years) 63.5 8.4 63.7 8.0 63.8 8.8 63 7.9 NS
Qmax (mL/s) 11.5 5.2 13.8 7.0 11.9 5.2 10.3 4.3 S
Prostate volume (cm3) 43 20 40.4 20 45 21 42 19 NS
Residual urine (mL) 48 71 44 86 41 61 60 80 S
IPSS total 17.0 7.0 5 1.9 14.1 3.2 24.5 3.6
IPSS voiding 9.7 4.8 2.6 1.8 7.9 2.9 14.4 3.0
IPSS filling 7.3 3.4 2.5 Î.8 6.3 2.6 10.0 2.4
Kfcr. IPSS - International Prostate Sym ptom  Score; NS = not signi/iamf; Qmax = maximum Jlow rate; SD =  standard devint ion; S == significant. •
obstructed; conversely, he is probably unob­
structed if Qmax is higher than 15 mL/s.8 Also, 
prostate size and its changes are especially relevant 
to the choice of treatment to surgically or non- 
surgically reduce prostatic bulk. Common practice 
dictates that the postvoid residual urine determi­
nation is a useful objective measurement of the 
effect of prostatic occlusion on the posterior ure­
thra. The Second International Consultation on 
BPH Committee recommended the measurement 
of postvoid residual urine in the diagnostic 
workup of patients with symptoms of LUTS due 
to BPH.9
Currently, no agreement exists among urologists 
concerning the minimal requirements for diagno­
sis and follow-up of patients with LUTS or BPH* 
Moreover, the correlation between several of these 
parameters has been questioned. The present 
study was conducted on a large series of patients 
to evaluate the relation between LUTS, as mea­
sured by IPSS, and objective noninvasive param­
eters of lower urinary tract function.
MATERIAL AND METHODS
We studied 803 consecutive patients with LUTS and/or 
BPH. All patients included in the present study were subjected 
to a standardized diagnostic program including history (in­
cluding IPSS), physical examination (including digital rectal 
examination), biochemistry (including prostate-specific an­
tigen), urinalysis and culture, urine cytology, and urody- 
namic investigations that included pressure-flow studies. Pa­
tients with a total IPSS of less than 8, 8 to .19, or greater than 
19 were considered to have mild, moderate, or severe symp­
toms, respectively.10 The total score of questions 2, 4, and 7 
represents the filling component of the IPSS, whereas the total 
score of questions 1, 3, 5, and 6 represents the voiding com­
ponent. Free uroflowmetry was performed in private when 
the patient presented with normal to severe urge to void. Flow 
was measured using a Dantec Urodyn 1000 flowmeter. Ac­
cording to Abrams and Griffiths,8 a maximum flow rate ex­
ceeding 15 mL/s generally indicates unobstructed micturi­
tion, whereas values below 10 mL/s indicate infravesical
obstruction, provided detrusor insufficiency is absent. Pa­
tients involved in uroflowmetry studies were considered for 
the study if the voided volume was 150 mL or greater. Sev­
enty-four patients did not fulfill this requirement. The data 
from the remaining 729 patients were used for analysis.
The prostate size was determined using the Kretz Combi- 
son 330 ultrasound scanner with a 7,5-MHz transrectal probe 
( Multi 3-D VRW 77 A K ), The prostate was imaged from base 
to apex; the presence of prostate abnormalities was docu­
mented, Prostate volume was measured by the planimetrie 
method.11 The same ultrasound scanner was used in combi­
nation with a transabdominal probe (Kretz AWP 3.5) for the 
estimation of urine residue directly after performing uroflow- 
me try.
For statistical analysis, we used descriptive statistics and 
the Spearman correlation coefficient ( r )  to describe the as­
sociation between IPSS questions and the various tested pa­
rameters. Comparisons among groups of symptom score were 
made using the Kruskal-Wallis test.
RESULTS
Descriptive statistics with respect to the patients5 
ages, flow results, prostate volumes, and postvoid­
ing residual urine measurements are summarized 
in Table I. The mean (±SD) age of the patients 
was 63.5 ± 8.4 years, and the mean total IPSS, the 
voiding subscore, and the filling subscore were 17 
± 7, 9.7 ± 4.8, and 7.3 ± 3.4, respectively. When 
the patients were classified according to the IPSS, 
the mild-symptom group included 71 patients, the 
moderate-symptom group included 392 patients, 
and the severe-symptom group included 266 pa­
tients. There were small but statistically significant 
differences between IPSS classes and Qmax and 
residual urine measurement. In Table II, we cor­
related the individual IPSS questions with each of 
the four parameters mentioned above. Interest­
ingly, we found only a small correlation between 
the Qmax and weak stream (question 5). The 
same holds for incomplete emptying of the bladder 
(question 1) and residual urine (r = 0.17). Sta­
tistically significant but weak correlations were 
also found between all questions of IPSS and
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TABLE II. Spearman correlation between the International Prostate Symptom Score questions 
and noninvasive parameters of lower urinary tract symptoms
Median Age Qmax Prostate Volume Residual Urine
IPSS 1 2 0.12 - 0.10 0.05 (NS) 0.17
IPSS2 3 0.04 (NS) ” 0.09 0.05 (NS) 0.13
IPSS3 2 0.06 (NS) -0.19 0.01 (NS) 0.09
IPSS4 2 0,06 (NS) -0.05 (NS) 0.15 0.07
IPSS5 4 0.07 -0.23 0.11 0.13
IPSS6 1 0.08 - 0.12 0.01 (NS) 0.14
IPSS7 2 0.16 -0.12 0.06 (NS) 0.10
Ql 4 0.06 (NS) -0.15 0.04 (NS) 0.18
IPSS total 17 0.05 (NS) - 0.20 0.03 (NS) 0.18
IPSS voiding 10 0.11 - 0.21 0.02 (NS) 0.17
IPSS filling 7 0.06 (NS) - 0.10 0.11 0.13
K f.y: IPSS = International Prostate Symptom Score; 
Jlow rate; QI =  quality o f  life.
NS - not statistica//}' signi/icant (a// other coefficients \\c rc  statistically significant at P <0.05); ymfix = maximum
* The correlation coefficient ranges fro m  —1 to +1, with — Í describing a perfect negative /inear, or straight line, relationship anil +i describing a pcrfcct positive linea?, 
or straight line, relationship.
Qmax and residual urine, and for prostate volume 
with questions 4 (urgency) and 5 (weak stream). 
All the tested parameters have a correlation with 
the total IPSS except prostate volume. In addition, 
the ages of the patients correlated significantly 
with Qmax, prostate volume, and residual urine 
but not with the total IPSS. However, all correla­
tions are small (Table III).
The relationship between the grade of total IPSS 
and the results of the Qmax is shown in Figure 
1A. An increase in the severity of symptoms sig­
nificantly correlates with a decrease in flow rate, 
but the overlap in flow rate between patients with 
different scores is considerable. Figures IB and 1C 
represent the relationships between postvoid re­
sidual urine measurements and prostate volumes 
and the different grade of the IPSS. A weak asso­
ciation exists between the residual urine and dif­
ferent grades of symptoms, but no correlation was 
found between prostate volume and severity of 
symptoms.
COMMENT
t
In the present study, we evaluated the relation­
ship between LUTS due to BPH as measured by 
IPSS and objective noninvasive parameters of 
lower urinary tract dysfunction. Our study shows 
that the overall symptom severity correlates only 
weakly with the results of uroflowmetry and post- 
voiding residual urine measurements. Symptom 
severity does not correlate at all with the prostate 
volume and ages of the patients. The weak corre­
lation between symptoms and urinary flow rate 
was shown before by Barry et al.10 However, prob­
lems with the urinary flow rate in regard to mea­
surement errors, systematic learning effect, and 
the main difference between physiologic outlet ob­
struction and the symptoms associated with BPH 
are known.6,7 As illustrated by Figure 1A, there is 
a weak association between severity of symptoms 
and urinary flow rate. This supports the hypo­
thesis that the symptoms may originate from neu- 
rophysiologic changes that may or may not be as­
sociated with histologic and anatomic BPH. From 
this we conclude that, for an individual patient, 
the lack of correlation between symptoms and 
flow rate results should not alter the diagnosis 
of BPH.
The relationship between prostate volume and 
parameters for bladder outlet obstruction has also 
been studied by others, in our study, it was 
shown that no correlation exists between the IPSS 
and prostate volume. This lack of correlation can 
occur because hyperplasia may be associated with 
striking lateral lobe enlargement but symptoms 
may be negligible if the degree of obstruction is 
not severe. Conversely, BPH may be associated 
with a relatively small-sized prostate and marked 
obstructive symptoms if the obstructing tissue 
originates exclusively within the central zone of 
the periurethral gland area.13 In Figure 1C, we 
demonstrated the absence of any relationship be­
tween prostate volume and the severity of symp­
toms.
Determination of postvoiding residual urine pro­
vides one of the most effective methods of evaluation 
of patients during a period of watchful waiting and 
monitoring response to treatment. Also, large studies 
on urodynamic results of surgical treatment of BPH 
have shown that the volume of residual urine sig­
nificantly decreases after surgery.14 In our study, we 
evaluated the relation between postvoiding residual 
urine and Qmax and severity of symptoms. A statis­
tically significant correlation was found among all 
IPSS questions and residual urine and Qmax. How-
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TABLE Hi. The International Prostate Symptom Score (IPSS)
1. Over the past month, 
how often have you 
had a sensation of 
not emptying your 
bladder completely 
after you finished 
urinating?
2. Over the past month, 
how often have you 
had to urinate again 
less than 2 hours 
after you finished 
urinating?
3. Over the past month, 
how often have you 
found you stopped 
and started again 
several times when 
you urinated?
4. Over the past month, 
how often have you 
found it difficult to 
postpone urination?
5. Over the past month, 
how often have you 
had a weak urinary 
system?
6 . Over the past month, 
how often have you 
had to push or strain 
to begin urination?
Not at 
All
Less Than 
1 Time 
in 5
Less Than 
Half the 
Time
About 
Half the 
Time
More Than 
Half the 
Time
0 1 2 3 4
0 1 2 3
0 1 2 3 4
0 1 2 3 4
0 1 2 3 4
0
None
1
1 Time
2
2 Times
3
3 Times
4
4 Times
Almost
Always
5
5
5
5
5
5
5 Times
7. Over the past month, 
how many times did 
you most typically 
get up to urinate 
from the time you 
went to bed at night 
until the time you got 
up in the morning? 0 1 2 3 4 5
TOTAL IPPS Score S = QUALITY OF LIFE DUE TO URINARY SYMPTOMS
Mixed About
Mostly Equally Satisfied Mostly 
Delighted Pleased Satisfied and Dissatisfied Dissatisfied Unhappy Terrible
1. If you were to spend 
the rest of your life 
with your urinary 
condition just the 
way it is now, how 
would you feel about 
this? 0 1 2 3 4 5 6
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FIGURE 1. The severity of symptoms according to 
three classes (miid less than 8, moderate 8 to 19, and 
severe greater than 19) and (A) the distribution of max­
imum flow rate (Qmax) classified into three classes (less 
than 10 mL/s [black area], 10 to 15mL/s [shaded area], 
and more than 15 mL/s [white area]), (B) the distribution 
of postvoiding residues classified into three classes (less 
than 50 mL [black area], 50 to 100 mL [shaded area], 
and more than 100 mL [white area]), and (C) the distri­
bution of prostate volume into three classes (less than 
30 cm5 [black area], 30 to 70 cm3 [shaded area], and 
more than 70 cm3 [white area]).
ever, the clinical significance of this finding is min- 
imal, because there exists a great overlap in symp­
tom score between patients with different grades of 
obstruction.
From the current study, we conclude that the 
correlation between the uroflowmetry results, 
prostate volume, postvoid residual urine, and 
LUTS as measured by the IPSS is weak. Moreover, 
the main problem in the documentation of out­
come of treatment of BPH consists of achieving 
agreement in the use of the different parameters. 
Should we aim at improvement of symptoms only, 
at improvement of the objective voiding parame­
ters, or even at improvement of both?
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